论文部分内容阅读
目的 探讨中等剂量紫杉醇化疗合并放疗对老年人晚期非小细胞肺癌 (NSCLC)治疗价值及耐受性。方法 将 62名老年晚期NSCLC病人随机分成 2组。治疗组 :应用紫杉醇 (太素 10 0～ 13 5mg/m2 )加卡铂 ( 2 0 0mg/m2 )化疗 2个疗程 ,胸部放疗 60Gy( 3 0次 ,每周 5次 ) ,放疗时每周加用 3 0mg紫杉醇。对照组 :应用CE方案加放疗。 结果 治疗组近期有效率为 62 .0 7% ,对照组为 3 4 .48% ,两组差异显著 (P <0 .0 5 )。治疗组对腺癌疗效好 ,有效率高于对照组 (P <0 .0 5 )。治疗组主要副反应为血液毒性 ,明显高于对照组 (P <0 .0 5 ) ,但严重骨髓抑制发生率低 ,放疗副反应两组无明显差异。结论 中等量紫杉醇化疗合并胸部放疗对老年晚期NSCLC是有效的 ,可以耐受。
Objective To investigate the value and tolerability of moderate-dose paclitaxel chemotherapy combined with radiotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods Sixty-two elderly patients with advanced NSCLC were randomly divided into two groups. Treatment group: paclitaxel (Tai Su 10 ~ 13 5mg / m2) plus carboplatin (200mg / m2) chemotherapy 2 courses, chest radiotherapy 60Gy (30 times a week, 5 times a week), radiotherapy weekly With 30mg paclitaxel. Control group: application of CE program plus radiotherapy. Results The effective rate was 62.07% in the treatment group and 34.48% in the control group, with significant difference between the two groups (P <0.05). The treatment group of adenocarcinoma effective, effective than the control group (P <0. 05). The main side effects of the treatment group was hematotoxicity, which was significantly higher than that of the control group (P <0.05). However, the incidence of severe myelosuppression was low and there was no significant difference between the two groups. Conclusions Moderate amount of paclitaxel chemotherapy combined with chest radiotherapy is effective and tolerable in elderly patients with advanced stage NSCLC.